相关实验视频

Updated: Sep 14, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

克里佐替尼:一种新的策略,通过向乳酸运输来逆转黑色素瘤的免疫抑制

Zhe Zhou^1,2,3,4,5, Xu Zhang^1,2,3,4,5, Susi Zhu^1,2,3,4,5

¹The Department of Dermatology Xiangya Hospital Central South University Changsha China.

|July 22, 2025

概括

小分子crizotinib抑制CD147-单碳酸载体1 (MCT1) 复合体,减少黑色素瘤的生长并增强免疫疗法. 这种代谢干预阻断了乳酸驱动的免疫抑制,提供了一个新的治疗策略.

科学领域:

在瘤学瘤学.
代谢过程中的代谢.
免疫学免疫学免疫学

背景情况:

乳酸是癌症中的关键代谢物,影响瘤的进展和存活.
CD147单碳酸盐载体1 (MCT1) 复合体对于乳酸运输至关重要,也是潜在的治疗点.
目前没有针对CD147-MCT1复合体的有效蛋白质-蛋白质相互作用 (PPI) 抑制剂.

研究的目的:

为了确定CD147-MCT1复合体的抑制剂.
为了研究破坏黑色素瘤中乳酸运输的治疗潜力.
探索代谢干预对瘤免疫微环境和免疫治疗反应的影响.

主要方法:

对CD147-MCT1复合物的小分子抑制剂进行查.
在体外测试测量乳酸分泌和吸收.
在体内研究评估瘤生长和对免疫治疗的反应.
流细胞计分析免疫细胞的两极分化.
转录组分析和表观遗传学研究 (基因组乳基化) 以阐明分子机制.

主要成果:

克里佐替尼有效地破坏了CD147-MCT1相互作用,减少乳酸分泌和吸收.
在体内,克里佐替尼治疗抑制了黑色素瘤瘤的生长,并改善了对免疫检查点阻塞的反应.
使用crizotinib的代谢干预抑制了M2巨分化,并重塑了瘤免疫微环境.
在巨细胞中,乳酸诱导的C-X-C动机化学因子联结体13 (CXCL13) 表达被crizotinib通过抑制基因素乳化抑制.
克里佐替尼逆转了乳酸驱动的转录重编程,通过减少CXCL13促进体的H3K18la丰富来证明这一点.

结论:

克里佐替尼是CD147-MCT1复合物的新型抑制剂,在黑色素瘤中具有治疗潜力.
破坏乳酸运输可以重新编程瘤的免疫微环境,并提高免疫治疗的疗效.
通过抑制CD147-MCT1来准代谢-免疫交叉,为改善癌症治疗结果提供了一个有希望的策略.

关键词:

CD147 是一个CD147 CD147 是一个CD147 在CXCL13中,CXCL13是最重要的.乳酸乳酸是一种乳酸.乳化乳化乳化单碳酸盐输送器 1 1

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...